LEI:
549300Q7EXQQH6KF7Z84
12 April
2024
RTW Biotech Opportunities
Ltd
Portfolio Company Update:
Artios Pharma
●
|
RTW's, Chris Liu PhD, joins the Artios Pharma Board of
Directors
|
●
|
The Company's holding in Artios Pharma was significantly
increased with the recent Arix transaction, making it one of the
top shareholders
|
RTW Biotech Opportunities Ltd (the
"Company"), a London Stock Exchange-listed investment company
focused on identifying transformative assets with high growth
potential across the life sciences sector, is pleased to announce
that Chris Liu, PhD has been appointed to the Board of Directors at
Artios Pharma ("Artios").
Chris is a Senior Research Analyst at RTW Investments, LP (the
"Investment Manager") where
he leads oncology research efforts.
In February 2024, RTW Biotech
Opportunities acquired the assets of Arix Bioscience, plc, of which
Artios Pharma was the largest position. The transaction
significantly added to the Company's existing position in Artios.
At 31 March 2024, Artios represented 4.6% of the Company's
NAV.
Artios is a Cambridge, UK-based
company developing breakthrough cancer treatments that target DNA
Damage Response (DDR) pathways to specifically destroy certain
devastating cancers that are difficult to treat.
Chris Liu, PhD, commented: "RTW is now a top shareholder of Artios following the
acquisition of Arix. The expansion of our equity interest reflects
our confidence and excitement in Artios' innovative platform
targeting broad aspects of the DNA damage response. I look forward
to partnering with the team and the Board to support them in their
mission to bring new therapies to patients suffering from difficult
to treat solid tumors."
Artios' announcement can be found on
their website:
https://artios.com/.
For
Further Information
RTW
Investments, LP
|
+44
20 7959 6361
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
Buchanan (PR & Communications Adviser)
|
+44
20 7466 5107
|
Charles Ryland
|
|
Henry Wilson
|
|
George Beale
|
|
|
|
Deutsche Numis (Joint Corporate Broker)
|
+44
20 7260 1000
|
Freddie Barnfield
|
|
Nathan Brown
|
|
Euan Brown
|
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
Edward Peel
|
|
Alex Penney
|
|
Cadarn Capital (Distribution & IR
Partner)
|
+44
73 6888 3211
|
David Harris
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44
14 8181 0100
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
***********